ZEVRA THERAPEUTICS: EXPECTS TO CONTINUE ENGAGEMENT WITH THE U.S. FDA IN THE H2 2026 TO EXPLORE PATHWAYS TO ACCELERATE CLINICAL DEVELOPMENT

Reuters · 2d ago

Please log in to view news